Guardant Health

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, with revenue of $335.0M exceeding expectations by 6.54% and non-GAAP EPS of -$0.42 outperforming the -$0.76 consensus. Performance was driven by a 257% YoY surge in Screening revenue and robust 63% growth in Oncology test volumes. While operating losses widened due to aggressive commercial scaling for Shield, management raised full-year FY26 revenue guidance to $1.34–$1.36B, well above previous targets.